Jae-Hoon Chung1, Brit L Martin1, Benjamin D Canan1, Mohammad T Elnakish1, Nima Milani-Nejad1, Nancy S Saad1, Steven J Repas1, J Eric J Schultz1, Jason D Murray1, Jessica L Slabaugh1, Rachel L Gearinger1, Jennifer Conkle1, Tallib Karaze1, Neha Rastogi1, Mei-Pian Chen1, Will Crecelius1, Kyra K Peczkowski1, Mark T Ziolo2, Vadim V Fedorov2, Ahmet Kilic3, Bryan A Whitson3, Robert S D Higgins3, Sakima A Smith4, Peter J Mohler5, Philip F Binkley4, Paul M L Janssen6. 1. Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States. 2. Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States. 3. Department of Surgery, The Ohio State University, Columbus, OH, United States. 4. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States; Department of Internal Medicine, The Ohio State University, Columbus, OH, United States. 5. Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States; Department of Internal Medicine, The Ohio State University, Columbus, OH, United States. 6. Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States; Department of Internal Medicine, The Ohio State University, Columbus, OH, United States. Electronic address: janssen.10@osu.edu.
Abstract
BACKGROUND: In patients with end-stage heart failure, the primary etiology often originates in the left ventricle, and eventually the contractile function of the right ventricle (RV) also becomes compromised. RV tissue-level deficits in contractile force and/or kinetics need quantification to understand involvement in ischemic and non-ischemic failing human myocardium. METHODS AND RESULTS: The human population suffering from heart failure is diverse, requiring many subjects to be studied in order to perform an adequately powered statistical analysis. From 2009-present we assessed live tissue-level contractile force and kinetics in isolated myocardial RV trabeculae from 44 non-failing and 41 failing human hearts. At 1 Hz stimulation rate (in vivo resting state) the developed active force was not different in non-failing compared to failing ischemic nor non-ischemic failing trabeculae. In sharp contrast, the kinetics of relaxation were significantly impacted by disease, with 50% relaxation time being significantly shorter in non-failing vs. non-ischemic failing, while the latter was still significantly shorter than ischemic failing. Gender did not significantly impact kinetics. Length-dependent activation was not impacted. Although baseline force was not impacted, contractile reserve was critically blunted. The force-frequency relation was positive in non-failing myocardium, but negative in both ischemic and non-ischemic myocardium, while the β-adrenergic response to isoproterenol was depressed in both pathologies. CONCLUSIONS: Force development at resting heart rate is not impacted by cardiac pathology, but kinetics are impaired and the magnitude of the impairment depends on the underlying etiology. Focusing on restoration of myocardial kinetics will likely have greater therapeutic potential than targeting force of contraction.
BACKGROUND: In patients with end-stage heart failure, the primary etiology often originates in the left ventricle, and eventually the contractile function of the right ventricle (RV) also becomes compromised. RV tissue-level deficits in contractile force and/or kinetics need quantification to understand involvement in ischemic and non-ischemic failing human myocardium. METHODS AND RESULTS: The human population suffering from heart failure is diverse, requiring many subjects to be studied in order to perform an adequately powered statistical analysis. From 2009-present we assessed live tissue-level contractile force and kinetics in isolated myocardial RV trabeculae from 44 non-failing and 41 failing human hearts. At 1 Hz stimulation rate (in vivo resting state) the developed active force was not different in non-failing compared to failing ischemic nor non-ischemic failing trabeculae. In sharp contrast, the kinetics of relaxation were significantly impacted by disease, with 50% relaxation time being significantly shorter in non-failing vs. non-ischemic failing, while the latter was still significantly shorter than ischemic failing. Gender did not significantly impact kinetics. Length-dependent activation was not impacted. Although baseline force was not impacted, contractile reserve was critically blunted. The force-frequency relation was positive in non-failing myocardium, but negative in both ischemic and non-ischemic myocardium, while the β-adrenergic response to isoproterenol was depressed in both pathologies. CONCLUSIONS: Force development at resting heart rate is not impacted by cardiac pathology, but kinetics are impaired and the magnitude of the impairment depends on the underlying etiology. Focusing on restoration of myocardial kinetics will likely have greater therapeutic potential than targeting force of contraction.
Authors: M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson Journal: N Engl J Med Date: 1982-07-22 Impact factor: 91.245
Authors: Nima Milani-Nejad; Benjamin D Canan; Mohammad T Elnakish; Jonathan P Davis; Jae-Hoon Chung; Vadim V Fedorov; Philip F Binkley; Robert S D Higgins; Ahmet Kilic; Peter J Mohler; Paul M L Janssen Journal: Am J Physiol Heart Circ Physiol Date: 2015-10-09 Impact factor: 4.733
Authors: Eric S Weiss; Jeremiah G Allen; Nishant D Patel; Stuart D Russell; William A Baumgartner; Ashish S Shah; John V Conte Journal: Circ Heart Fail Date: 2009-07-08 Impact factor: 8.790
Authors: Jae-Hoon Chung; Nima Milani-Nejad; Jonathan P Davis; Noah Weisleder; Bryan A Whitson; Peter J Mohler; Paul M L Janssen Journal: Am J Physiol Heart Circ Physiol Date: 2019-07-26 Impact factor: 4.733
Authors: Mei-Pian Chen; Salome A Kiduko; Nancy S Saad; Benjamin D Canan; Ahmet Kilic; Peter J Mohler; Paul M L Janssen Journal: Cardiovasc Res Date: 2020-01-01 Impact factor: 10.787
Authors: Jennifer M Petrosino; Jacob Z Longenecker; Srinivasagan Ramkumar; Xianyao Xu; Lisa E Dorn; Anna Bratasz; Lianbo Yu; Santosh Maurya; Vladimir Tolstikov; Valerie Bussberg; Paul Ml Janssen; Muthu Periasamy; Michael A Kiebish; Gregg Duester; Johannes von Lintig; Ouliana Ziouzenkova; Federica Accornero Journal: J Clin Invest Date: 2021-02-15 Impact factor: 14.808
Authors: Mohammed A Mashali; Nancy S Saad; Benjamin D Canan; Mohammad T Elnakish; Nima Milani-Nejad; Jae-Hoon Chung; Eric J Schultz; Salome A Kiduko; Amanda W Huang; Austin N Hare; Kyra K Peczkowski; Farbod Fazlollahi; Brit L Martin; Jason D Murray; Courtney M Campbell; Ahmet Kilic; Bryan A Whitson; Nahush A Mokadam; Peter J Mohler; Paul M L Janssen Journal: J Mol Cell Cardiol Date: 2021-03-22 Impact factor: 5.763
Authors: Kerry S McDonald; Laurin M Hanft; Joel C Robinett; Maya Guglin; Kenneth S Campbell Journal: Front Physiol Date: 2020-05-25 Impact factor: 4.566